

Recall the WM basics before diving into WM breakthroughs at EHA with memo inHaematology's exclusive interviews and reports

Epidemiology^{1,2}


Age-adjusted incidence

0.42 per 100,000 men and women per year

Median age at diagnosis

71 years

5-year relative survival




Genetic markers and their frequency in FL²⁻⁴

Genetic marker	Frequency	Clinical significance
MYD88	~95% – 96%	hallmark of WM
CXCR4	~40%	predictive and prognostic value
TP53	<14%	decreased survival

Revised International scoring system for Waldenström's macroglobulinemia (ISSWM)^{5,6}

- Age < 65 (0 points)
- Age 66-75 years (1 point)
- Age > 75 (2 points)
- β 2-microglobulin \geq 4mg/L (1 point)
- LDH > 250 IU/L (1 point)
- Serum albumin < 3.5 g/dL (1 point)


5-year survival by FLIPI risk categories⁶



Treatment choice is guided by multiple factors and geared to each patient's situation. For many patients with newly diagnosed or relapsed WM, a watch-and-wait strategy is appropriate. However, if symptoms compromise quality of life, treatment is indicated. The recommended treatment regimens according to the NCCN guidelines for the management of patients with WM are summarized based on the figure.⁷

New investigational agents for WM that are currently being assessed in recruiting phase 2 and phase 3 trials as monotherapies or in combination with other drugs are alphabetically listed below.⁸

- ADC: ioncastuximab tesirine
- Anti-CD20 AB: obinutuzumab
- BCL2i: BGB-11417
- BTK degrader: BGB-16673
- CAR T-cell therapies: brexucabtagene autoleucel, MB-106
- DNMTis: **azacitidine**
- Immunomodulatory agent: lenalidomide
- nc-BTKi: nemtabrutinib, pirtobrutinib
- SINEs: selinexor
- Targeted radiotherapy: lopotofosine I 131



References: • 1 Gertz MA. Am J Hematol. 2023 Feb;98(2):348-358. • 2 Castillo JJ, et al. Blood. 2014 June;123(25):3999-4000. • 3 Castillo JJ, et al. Blood Adv. 2022 Feb;6(3):1015-1024. • 4 Tam CS, et al. Blood Adv. 2024 Apr 9;8(7):1639-1650. • 5 Morel P, et al. Blood. 2009 April;113(18):4163-4170. • 6 Kastritis E, et al. Leukemia. 2019 Nov;33(11):2654-2661. • 7 National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version 2.2024 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. Accessed May 23, 2024, https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf • 8 Clinicaltrials.gov. (2024). Accessed: 27052024